These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 25637792)

  • 1. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
    Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
    Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
    Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
    Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
    Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.